A master regulator of growth, survival, and cellular metabolism, PI3K is commonly altered in CRC via mutations in PIK3CA, a loss of PTEN, the amplification of IGF2, and mutations in AKT1, contributing to tumor progression, therapeutic resistance, and poor outcomes [15,16,17,18,19,20,21]. The gene discussed is PIK3CA; the disease is neoplasm.